Zobrazeno 81 - 90
of 4 081
pro vyhledávání: '"RC254-282"'
Autor:
Cinzia Brunelli, Emanuela Zito, Sara Alfieri, Claudia Borreani, Anna Roli, Augusto Caraceni, Giovanni Apolone
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Despite evidence of the positive impact of routine assessment of patient-reported outcome measures (PROMs), their systematic collection is not widely implemented in cancer care. Aim To assess the knowledge, use and attitudes of healthcare
Autor:
Courtney Andrews, Timothy C. Childers, Kimberly D. Wiseman, Valerie Lawhon, Stacey Ingram, Mary Lou Smith, Antonio C. Wolff, Lynne Wagner, Gabrielle B. Rocque
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
BMC Cancer
BMC Cancer
Background As the combination of systemic and targeted chemotherapies is associated with severe adverse side effects and long-term health complications, there is interest in reducing treatment intensity for patients with early-stage breast cancer (EB
Autor:
Tomoko Yoshida, Kazuhiko Takeda, Toshihiko Kaneda, Hiroaki Yanagimoto, Takao Yoshida, Kayoko Kibata, Koji Tsuta, Takayasu Kurata, Hiroshige Yoshioka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy
Autor:
Stefania Tommasi, Letizia Porcelli, Roberta Di Fonte, Simona De Summa, Rosanna Lacalamita, Amalia Azzariti, Brunella Pilato, Katia Danza, Simona Serratì
Publikováno v:
Molecular Oncology, Vol 16, Iss 4, Pp 904-920 (2022)
Vitamin D is used to reduce cancer risk and improve the outcome of cancer patients, but the vitamin D receptor (VDR; also known as the calcitriol receptor) pathway needs to be functionally intact to ensure the biological effects of circulating calcit
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-6 (2022)
Purpose Estrogen-receptor (ER) and progesterone-receptor (PR) expression levels in breast cancer, which have been principally compared via binomial descriptors, can vary widely across tumors. We sought to characterize ER and PR expression levels usin
Autor:
Mohit Jadli, Joni Yadav, Nikita Aggarwal, Arun Chhokar, Veera Mohan Veerapandian, Kulbhushan Thakur, Tejveer Singh, Tanya Tripathi, Alok C. Bharti, Anjali Bhat
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-16 (2022)
Background Exosomes play a key role in cell-to-cell communication and are integral component of the tumor microenvironment. Recent observations suggest transfer of RNA through tumor-derived exosomes that can potentially translate into regulatory prot
Publikováno v:
Cancer Medicine, Vol 11, Iss 3, Pp 764-777 (2022)
Objective Male breast cancer (BC) is a rare disease, having different clinicopathological features and survival outcomes from female patients. The aim of this research was to, combine with molecular subtypes, analyze the metastatic patterns, and prog
Autor:
Akdeniz, D., Barele, M. van, Heemskerk-Gerritsen, B.A.M., Steyerberg, E.W., Hauptmann, M., Beek, I. van de, Engelen, K. van, Wevers, M.R., Garcia, E.B.G., Ausems, M.G.E.M., Berger, L.P.V., Asperen, C.J. van, Adank, M.A., Collee, M.J., Stommel-Jenner, D.J., Jager, A., Schmidt, M.K., Hooning, M.J., HEBON Investigators
Publikováno v:
HEBON Investigators 2021, ' Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers : A nationwide cohort study ', Breast, vol. 61, pp. 98-107 . https://doi.org/10.1016/j.breast.2021.12.007
The Breast : Official Journal of the European Society of Mastology
Breast, 61, 98-107. Churchill Livingstone
Breast, 61, 98-107
The Breast, 61, 98-107. CHURCHILL LIVINGSTONE
Breast, Vol 61, Iss, Pp 98-107 (2022)
Breast, 61, pp. 98-107
The Breast : Official Journal of the European Society of Mastology
Breast, 61, 98-107. Churchill Livingstone
Breast, 61, 98-107
The Breast, 61, 98-107. CHURCHILL LIVINGSTONE
Breast, Vol 61, Iss, Pp 98-107 (2022)
Breast, 61, pp. 98-107
Aim BRCA1/2 mutation carriers with primary breast cancer (PBC) are at high risk of contralateral breast cancer (CBC). In a nationwide cohort, we investigated the effects of chemotherapeutic agents given for PBC on CBC risk separately in BRCA1 and BRC
Autor:
Yih-Leong Chang, Chiau-Jing Jung, Song-Chou Hsieh, Lo Chiao, Yi-Ming Huang, Chen-Han Chang, Ching-Hung Lin, Yu Min Kuo
Publikováno v:
Breast, Vol 61, Iss, Pp 35-42 (2022)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Targeted therapies against human epidermal growth factor receptor 2 (HER2) are associated with increased interstitial lung disease (ILD). Trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended HER2 breast cancer survival
Autor:
Linn Weick, Mattias Lidén, Christian Jepsen, Emmelie Widmark Jensen, Fredrik Brorson, Emma Hansson
Publikováno v:
Breast, Vol 61, Iss, Pp 91-97 (2022)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Background There are three patient reported outcome measure instruments (PROMs) that have adequate content validity for breast reconstruction, BREAST-Q, BRECON-31 and EORTC QLQ-BRECON-23, and they all have been robustly validated. The aim of this stu